Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07216131 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Effect of AZD0780 on Metformin Pharmacokinetics in Healthy Adult Volunteers Aged 18 to 55 Years
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT07216131 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 14 participants.
The verdict
NCT07216131, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to determine how the experimental medication AZD0780 impacts the pharmacokinetics (PK) of metformin, a common medication used to treat type 2 diabetes mellitus, when given together in healthy participants.
Interventions
- DRUG Metformin
- DRUG AZD0780
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2025-11-10 |
| Est. Completion | 2025-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07216131
The ClinicalTrials.gov registry entry for NCT07216131 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Metformin is the first listed.
NCT07216131 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07216131 about?
NCT07216131 is a clinical study titled "A Study to Investigate the Effect of AZD0780 on Metformin Pharmacokinetics in Healthy Adult Volunteers Aged 18 to 55 Years". The purpose of this study is to determine how the experimental medication AZD0780 impacts the pharmacokinetics (PK) of metformin, a common medication used to treat type 2 diabetes mellitus, when given together in healthy participants.
What is the current status of trial NCT07216131?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2025-11-10. Estimated completion is 2025-12-30.
What interventions are being tested in trial NCT07216131?
The interventions under investigation include: Metformin (DRUG), AZD0780 (DRUG).
Who is sponsoring clinical trial NCT07216131?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.